Skip to main content

Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv

The Eli Lilly compnay hits $1 trillion in market value

A drone view shows the Eli Lilly logo on one of the company’s offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake Purchase Licensing Rights, opens new tab

July 15 (Reuters) - Eli Lilly (LLY.N), opens new tab is ​in talks to acquire psychedelic drugmaker ‌AtaiBeckley (ATAI.O), opens new tab and a deal could be announced as soon as this week, Bloomberg News ​reported on Wednesday, citing people ​familiar with the matter.

AtaiBeckley shares soared 66% ⁠in aftermarket trading, while Lilly ​was flat. AtaiBeckley was up 31% so far ​this year and had a market value of $1.97 billion as of Wednesday's close, according to ​LSEG data.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Lilly is negotiating a deal ​at a premium, Bloomberg News said.

Eli Lilly and ‌AtaiBeckley ⁠were not immediately available for comment outside regular business hours.

New York-based AtaiBeckley focuses on psychedelic-based treatments for mental health ​conditions and is developing ​BPL-003, ⁠an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.

The company's shares ​received a boost this year ​after ⁠U.S. President Donald Trump ordered health regulators to speed up reviews of psychedelic treatments ⁠and ​increased federal funding for ​their research.

Reporting by Fabiola Arámburo in Mexico City; ​Editing by Tasim Zahid and Jonathan Ananda

Our Standards: The Thomson Reuters Trust Principles., opens new tab

  • X

  • Facebook

  • Linkedin

  • Email

  • Link

Purchase Licensing Rights

Read Next

Trump CDC nominee sidesteps questions on standing up to Kennedy on vaccines

Erica Schwartz and Sean Kaufman testify before a Senate Health, Education, Labor, and Pensions Committee confirmation hearing on Capitol Hill

  • 5 hours agoANALYSIS

Chinese drugmakers with big ambitions struggle to recruit staff for global expansion

Hengrui Pharma office in Shanghai

French parliament approves landmark assisted-dying bill

French parliament votes on the end-of-life bill in Paris

US says it is blocking Americans in DR Congo from immediate travel home, citing Ebola

People travel in airports across the US

Hegseth announces testosterone screening for US troops

Briefing amid the U.S.-Israeli conflict with Iran, at the Pentagon

Novo Nordisk wins EU approval for Wegovy weight-loss pill

An illustration photo shows a box of Wegovy (semaglutide) tablets in Schwenksville

Business

  • Media tour at "Syngenta Group China" in Wei county of Handan

Syngenta's $5 billion HK IPO pushed back amid agriculture sector uncertainty, Bloomberg News reports

Legalcategory · July 16, 2026 · 12:41 AM EDT · 17 mins ago

Swiss agricultural chemicals and seeds company Syngenta's planned $5 ​billion Hong Kong IPO is ‌facing delays as the company awaits better conditions in the sector, Bloomberg News ​reported on Thursday, citing ​people familiar with the matter.

  • SK Hynix at the Nasdaq market in New York

category Morning Bid: This AI, it will make a profit, right?

12:32 AM EDT

  • A salesperson shows a gold ring to customers at a jewellery showroom in Ahmedabad

Businesscategory Gold falls as Mideast escalation dims hopes of easing inflation

12:19 AM EDT

  • A trader sits in front of the computer screens at his desk at the Frankfurt stock exchange

Financecategory Europe Inc heads into strongest earnings season in years, but AI gap persists

12:05 AM EDT

  • A delivery worker walks next to a Chinese national flag, in Beijing

ANALYSIS China's record consumer defaults undermine Beijing's push to boost spending

12:04 AM EDT

Read Original at Reuters →